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Abstract Protein tyrosine phosphatase 1B (PTP1B) is a
non-transmembrane protein tyrosine phosphatase that has
come into focus as a critical regulator of multiple signaling
pathways. The role of PTP1B in breast cancer remains
unclear with evidence suggesting that PTP1B can exert both
tumor-suppressing and tumor-promoting effects. To better
define the role of PTP1B in human breast cancer, and its
relationship with HER2, we performed immunohistochem-
ical studies on a large cohort of functionally annotated
primary breast cancer specimens. 683 of 1,402 (49 %)
evaluable primary breast cancers are positive for PTP1B.
There is no statistically significant association between
PTP1B expression and age, tumor size, T stage, histologic
grade, lymph node status, or histological subtype. Of note,
there is no significant association between PTP1B expres-
sion and HER2 expression (PTP1B expression 53.1 % in
HER2? cancers vs. 47.5 % in HER2- cancers, p = 0.0985).
However, PTP1B expression is significantly associated with
estrogen receptor expression (PTP1B expression 50.7 % in
ER? cancers vs. 43.1 % in ER- cancers, p = 0.0137) and
intrinsic molecular subtype (PTP1B expression 53.9 % in
the luminal B HER2? subtype and 37.9 % in the basal-like
subtype). Of note, multivariate analyses demonstrate that
PTP1B is an independent predictor of improved survival in
breast cancer (HR 0.779, p = 0.006). Taken together, we
demonstrate in the largest study to date that (1) PTP1B is
commonly expressed in breast cancer, (2) there is no asso-
ciation or functional impact of PTP1B expression in HER2?
breast cancer, and (3) PTP1B expression in breast cancer is
associated with significantly improved clinical outcome.
Until additional studies are performed, caution should be
exercised in using PTP1B inhibitors in human breast cancer.
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Introduction
Reversible tyrosine phosphorylation, which is controlled
by the opposite actions of protein tyrosine kinases and
protein tyrosine phosphatases, constitutes an important
mechanism for regulating diverse physiological processes
such as cell growth, intercellular communication, cell
adhesion, and migration [1, 2]. The protein tyrosine phos-
phatase 1B (PTP1B) is a non-transmembrane protein
tyrosine phosphatase that is located on the cytoplasmic face
of the endoplasmic reticulum and has recently come into
focus as an important regulator of signaling pathways
involved in human diseases such as diabetes, obesity, and
cancer [3]. The multiple substrates of PTP1B are associated
with diverse cellular processes involving proliferation,
apoptosis, intercellular adhesion, and differentiation and
include receptor tyrosine kinases, transcription factors, and
cytoskeletal proteins [3]. Of note, PTP1B dephosphorylates
the insulin receptor and its primary substrates as well as the
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tyrosine kinase JAK2, a downstream element of the leptin
signaling cascade and thus serves as an inhibitor of the
insulin and leptin signaling pathways [4–6]. Other impor-
tant substrates of PTP1B include the Src homology phos-
photyrosyl phosphatase (SHP) 1 and 2, the epithelial
growth factor receptor (EGFR), and the platelet-derived
growth factor receptor (PDGFR) [1].
While the biology of PTP1B as a negative regulator of
the insulin and leptin signaling pathways has been exten-
sively studied, its role in cancer metabolism remains
unclear. Experimental evidence suggests that PTP1B can
exert both tumor-suppressing and tumor-promoting effects.
As many oncogenes encode proteins with a tyrosine kinase
activity that appears to be directly involved in the process
of transformation, overexpression of protein tyrosine
phosphatases, which remove phosphate from tyrosine res-
idues, are intuitive tumor suppressors. Consistent with this
hypothesis, studies have shown that PTP1B overexpression
diminishes tumorigenecity in transformed mouse fibro-
blasts [7, 8], and several reports suggest that PTP1B can
promote apoptosis through down-regulation of pro-survival
signaling [9, 10], enhancement of stress signaling [11], or
facilitation of caspase activities [3, 12]. Consistent with
this hypothesis is the finding that p53 and PTP1B double
knockout mice show an increase of B cell lymphomas and
a decreased survival when compared to p53-only knockout
mice [13].
In contrast to these findings, there is evidence that
PTP1B might act as a tumor promoter. For example,
upregulation of PTP1B was associated with increased
tumor growth in colon cancer cell lines [14], and it has
been shown that PTP1B is able to block anti-tumor sig-
naling pathways in carcinoma and lymphoma cell lines
[15]. Additional evidence for a role of PTP1B in promoting
tumorigenesis has come from studies of human cancers.
Immunohistochemical studies looking at the expression of
PTP1B in tumor cells found that it was upregulated in
80 % of ovarian carcinomas [16] and also elevated in
squamous cell carcinomas when compared to normal
human skin [17]. In addition, a recent report by Lessard
et al. [18] suggests a tumor-promoting role of PTP1B in
human prostate cancer.
The role of PTP1B has been studied most extensively in
breast cancer, with several studies focused on the potential
association of PTP1B with the human epidermal growth
factor receptor 2 (HER2), and the potential for PTP1B to
modulate HER2 signaling. In an important study by Wiener
et al. [19], 21 out of 29 human breast cancers stained
strongly for PTP1B when compared to normal breast tis-
sue, and overexpression of PTP1B was noted in 11 out of
12 HER2? cases. This strong association between PTP1B
and HER2 expression suggests that PTP1B and HER2 may
cooperate in the pathogenesis of this subtype of breast
cancers. Two recent studies independently support this
hypothesis, showing that PTP1B deficiency delays tumor
progression and protects against lung metastasis in an
activated HER2-induced genetically engineered mouse
model of human breast cancer [20, 21]. In this model, both
genetic deletion of PTP1B activity in the NDL2 transgenic
mice, as well as chemical inhibition of PTP1B, delayed the
time of tumor onset [20]. Importantly, PTP1B-deficient
mice were not universally protected against the develop-
ment of mammary tumors, as mammary tumors actuated by
the polyoma middle T antigen were not affected by loss of
PTP1B [21]. PTP1B therefore seems to have a selective
affirmatory role in HER2 signaling [22], and even seems to
be required for HER2-dependent transformation of human
breast epithelial cells [23]. In contrast, in an older study, it
was shown that PTP1B was capable of suppressing onco-
genic transformation by HER2 [8]. Supporting a possible
oncogenic role of PTP1B in breast cancer is the finding that
overexpression of PTP1B in the mouse mammary gland
leads to spontaneous mammary tumor development, sug-
gesting that this tyrosine phosphatase can act as an onco-
gene on its own [20]. In humans, overexpression of PTP1B
in breast epithelial cells distorts the normal acinar mor-
phology and causes uninhibited proliferation and loss of
polarity [23].
The pharmaceutical industry has developed a consider-
able interest in PTP1B as a potential drug target, as its
inhibition might help control a number of common diseases
such as adult-onset diabetes and obesity. Based on the
studies reviewed above highlighting a potential role for
PTP1B in HER2-mediated breast cancer, investigators
have also proposed targeting this molecule in human breast
cancer. To further explore the role of PTP1B in human
breast cancer, we conducted an immunohistochemical
study on a breast cancer tissue microarray (TMA)
encompassing a total of 1,402 formalin-fixed breast cancer
cases with detailed clinical annotation and outcomes data.
The aim of our study was to investigate the association
between PTP1B and HER2 and other clinicopathological
parameters in breast cancer, and to study the impact of
PTP1B on prognosis. The data are reported according to
the Reporting recommendations for tumor marker prog-
nostic studies (REMARK) [24].
Materials and methods
Tissue microarray
We used a TMA encompassing 2,020 breast cancer tissue
punches from 1,579 formalin-fixed and paraffin-embedded
tumor samples collected from patients diagnosed with
primary breast cancer between 1985 and 2007 at the
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Institute for Pathology, University of Basel and the Viollier
Institute in Basel, Switzerland. Of these 2,020 tissue pun-
ches, a total of 1,402 were evaluable for our study. The
tissue samples were brought into a TMA format as previ-
ously described [25]. In brief, 0.6-mm tissue cylinders were
punched out of donor tumor tissue blocks and transferred
into a recipient paraffin block using a semi-automated tis-
sue arrayer. Each TMA contained a number of tumor
punches ranging from 159 to 522. Histopathological data
were obtained from the pathology reports, and raw patient
survival data were obtained from the Cancer Registry of
Basel or from the patient’s attending physician. Retrieval
of tissue and clinical data was performed according to the
regulations of the local institutional review boards and data
safety laws with specific regard to ethical standards and
patient confidentiality. The mean follow-up time was
80.8 months (range 1–263 months), and the median age of
the patients was 63 years (range 27–101 years). Demo-
graphic information of the patients can be found in
Table 1.
Immunohistochemistry
For immunohistochemical staining, 4-lm sections of the
TMA blocks were incubated overnight with the primary
monoclonal anti-PTP1B antibody (Epitomics Inc., Catalog
Nr. 2066-1, CA, USA) in a dilution of 1:200 after heat-
induced antigen retrieval with Citrate buffer at pH 6.
Standard DAB technique (Dako EnVision ? System-
labeled Polymer Anti-rabbit followed by Liquid
DAB ? Substrate Chromogen System) was employed for
immunostaining. Counterstaining was performed with
hematoxylin solution. The percentage of cells with a dis-
tinctive strong cytoplasmic staining was estimated. All
cases with a cytoplasmic PTP1B expression of C5 % were
considered positive for PTP1B expression. The staining
intensity of ER, PR, and HER2 was scored as described
previously [26]. In brief, tumors were considered positive
for ER if they showed nuclear staining in more than 10 %
of tumor cells with an intensity score between 1 and 3.
Statistical analysis
The distributions of patient and clinical characteristics
between PTP1B-positive and PTP1B-negative tumors were
compared using Chi-square test, Wilcoxon rank sum test,
or two-sample t test, as appropriate. The strength of asso-
ciation between PTP1B expression and other continuous or
ordinal factors (such as tumor size and ER expression) was
also described using Spearman’s correlation coefficients
(q). Overall survival (OS) was defined as the time from the
first operation to death due to any cause. Survivors were
censored at the date of last contact. Survival curves by
PTP1B status were estimated using the Kaplan–Meier
product-limit method and compared by log-rank test.
Univariate Cox proportional hazard models were fit to
identify factors significantly related to OS. To assess
whether PTP1B was an independent predictor of survival, a
multivariate Cox model was constructed to adjust other
patient/clinical characteristics that were significant in the
univariate analyses. Two-way interaction terms between
PTP1B and other factors in the multivariate Cox model
were also assessed. All analyses were two-sided and sig-
nificance was set at a p value of 0.05. Statistical analyses
were performed using SAS (SAS Institutes, Cary, NC).
Table 1 Demographic data
Clinicopathologic parameter
Mean age at diagnosis (years) 63.5
Mean tumor size (mm) 30.7
n (%)
Tumor grade
1 324 (23.1)
2 576 (41.1)
3 502 (35.8)
Tumor size
pT1 385 (27.5)
pT2 738 (52.6)
pT3 107 (7.6)
pT4 172 (12.3)
Lymph node stage
pN0 725 (51.8)
pN1 540 (38.6)
pN2 134 (9.6)
Histological subtype
Invasive ductal 993 (70.9)
Invasive lobular 203 (14.5)
Mucinous 38 (2.7)
Apocrine 17 (1.2)
Cribriform 41 (2.9)
Papillary 19 (1.3)
Medullary 45 (3.2)
Other 44 (3.1)
Molecular subtype
Luminal A (ER? and/or PR?,
HER2-, Ki-67 \ 14 %)
218 (15.6)
Luminal B (HER2-negative)
ER? and/or PR?, HER2-, Ki-67 C 14 %)
683 (48.9)
Luminal B (HER2-positive)
(ER? and/or PR?, HER2?)
156 (11.2)
HER2 type (ER- or PR-, HER2?) 111 (7.9)
Basal-like (ER-, PR-, HER2-) 227 (16.2)
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Results
Consistent with the known intracellular localization of
PTP1B, breast cancers expressing PTP1B showed strong
cytoplasmic staining of PTP1B (Fig. 1). Using a threshold
of C5 % of cancer cells staining positive for PTP1B, a total
of 683 (49 %) of the 1,402 evaluable primary breast can-
cers were positive for PTP1B. PTP1B expression was not
significantly associated with tumor size, age at diagnosis,
tumor stage, tumor grade, lymph node status (Table 2), or
histological subtype (data not shown). Of note, there was
no significant association between PTP1B expression and
HER2 expression (PTP1B expression 53.1 % in HER2?
cancers vs. 47.5 % in HER2- cancers, p = 0.0985, and
Spearman’s q = -0.04, Table 2). However, we did find a
small, but statistically significant association between
PTP1B expression and ER status (PTP1B expres-
sion 50.7 % in ER? cancers vs. 43.1 % in ER- cancers,
p = 0.0137, and Spearman’s q = -0.07, Table 2). In
addition, PTP1B expression is associated with the intrinsic
subtypes of breast cancer, as defined by the St. Gallen
consensus conference. The breast cancer intrinsic subtypes
were originally defined by gene expression profiling [27,
28] but can be approximated using immunohistochemistry
for estrogen receptor (ER), progesterone receptor (PR), Ki-
67, and HER2 [29, 30]. These subtypes are known to have
differing epidemiological risk factors, prognosis, and
response to therapy [29]. PTP1B expression was highest in
the luminal B HER2? subtype (53.9 %) and lowest in the
basal-like subtype (37.9 %, p = 0.008) (Table 3).
Studying the impact of PTP1B expression on survival,
we found that in univariate survival analyses, breast cancer
cases with positive PTP1B expression had a significantly
better OS (hazard ratio (HR) = 0.763, p = 0.002)
(Table 4; Fig. 2). In multivariate analyses, after adjusting
for age, grade, tumor size, lymph node status, and intrinsic
subtype, PTP1B remained an independent positive prog-
nostic factor for OS (HR = 0.779, p = 0.006) (Table 5).
In subset analyses of the specific intrinsic subtypes, PTP1B
expression proved to be an independent prognostic factor
for OS in the luminal B HER2- type, where positive
PTP1B expression was associated with significantly better
OS (HR = 0.661, p = 0.002) (Table 4; Fig. 3). The
luminal A subtype also showed a strong trend toward
improved OS with PTP1B expression (HR = 0.568,
p = 0.051) (Table 4; Fig. 3), but this was not statistically
significant. Of note, PTP1B expression did not have a
significant impact on OS in HER2? cases (Table 4; Fig. 5).
Fig. 1 a PTP1B staining of a primary invasive ductal breast cancer with cytoplasmic staining of 50 % of cells (PTP1B, 9400), b invasive ductal
breast cancer negative for PTP1B staining (PTP1B, 9400)
Table 2 Association between PTP1B expression and clinicopatho-
logical parameters
Clinicopathologic
parameter
PTP1B-
positive
PTP1B-
negative
Spearman’s q p value
Mean tumor size (mm) 30.6 30.7 0.019 0.4797
Mean age at diagnosis (years) 63.1 63.8 -0.029 0.3159
n (%) n (%) Spearman’s q p value
Tumor stage 0.017 0.6283
pT1 178 (46.2) 207 (53.7)
pT2 371 (50.3) 367 (49.7)
pT3 52 (48.6) 55 (51.4)
pT4 82 (47.7) 90 (52.3)
Tumor grade -0.018 0.4753
1 157 (48.5) 167 (51.5)
2 291 (50.5) 285 (49.5)
3 235 (46.8) 267 (53.2)
Lymph node stage -0.026 0.6210
pN0 363 (50.1) 362 (49.9)
pN1 257 (47.6) 283 (52.4)
pN2 63 (47.0) 71 (52.9)
Estrogen receptor -0.066 0.0137
ER? 527 (50.7) 513 (49.3)
ER- 153 (43.1) 202 (56.9)
HER2 -0.044 0.0985
HER2? 142 (53.1) 125 (46.8)
HER2- 537 (47.5) 592 (52.4)
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However, PTP1B expression did have a positive effect on
OS in ER? cases (HR = 0.693, p \ 0.001), but not in ER-
cases (HR = 1.082, p = 0.733) (Table 4; Fig. 4).
Discussion
In our study, we evaluated the expression of PTP1B in a large
cohort of functionally annotated primary breast cancer
specimens. We observed that PTP1B is expressed in 49 % of
primary breast cancers. This is in contrast to the report by
Wiener et al. [19], who observed PTP1B expression in 73 %
of primary breast cancers. Their collective, however, was
fairly small (n = 29), and the authors used a different eval-
uation system where they assigned expression intensities of
0–3? to the tissues and considered 2? and 3? as positive. The
Table 3 Association between PTP1B expression and breast cancer intrinsic subtypes
Molecular subtype PTP1B-positive (n) % PTP1B-negative (n) % p value
Luminal A (ER? and/or PR?, HER2-, Ki-67 \14 %) 107 49.1 111 50.9 \0.008
Luminal B (HER2-negative) ER? and/or PR?, HER2-, Ki-67 C 14 %) 344 50.4 339 49.6
Luminal B (HER2-positive) (ER? and/or PR?, HER2?) 84 53.9 72 46.1
HER2 type (ER- or PR-, HER2?) 58 52.2 53 47.8
Basal-like (ER-, PR-, HER2-) 86 37.9 141 62.1
Table 4 Univariate analyses for the effect of PTP1B on OS, as well
as the interaction effect between PTP1B and other factors (ER and
HER2 status, intrinsic subtype)
Hazard ratio (95 % CI) p value
All cases
PTP1B C5 % 0.763 (0.641–0.908) 0.002
Interaction with ER status 0.019*
ER? 0.693 (0.561–0.858) 0.001
ER- 1.082 (0.797–1.468) 0.733
Interaction with HER2 status 0.129*
HER2? 0.972 (0.677–1.396) 0.896
HER2- 0.706 (0.578–0.862) \0.001
Interaction with intrinsic subtype 0.049*
Luminal A 0.568 (0.321–1.003) 0.051
Luminal B (HER2-) 0.661 (0.510–0.856) 0.002
Luminal B (HER2?) 0.994 (0.607–1.629) 0.981
HER2 type 0.999 (0.586–1.705) 0.998
Basal-like 1.107 (0.751–1.632) 0.607
* p values for interaction terms
Fig. 2 Kaplan–Meier survival curve for OS depending on PTP1B
expression (univariate analysis). PTP1B positive cases show
significantly better OS
Table 5 Multivariate analysis for the effect of PTP1B on OS
Clinicopathologic parameter Hazard ratio (95 % CI) p value
PTPB1 = 0 % (reference) 1
PTP1B C5 % 0.779 (0.651–0.930) 0.006
Age (per 1-year) 1.037 (1.030–1.045) \0.001
Tumor grade
BRE grade 1 (reference) 1
2 1.622 (1.227–2.145) \0.001
3 2.614 (1.955–3.495) \0.001
Tumor stage
pT1 (reference) 1
pT2 1.6523 (1.272–2.147) \0.001
pT3 2.139 (1.483–3.086) \0.001
pT4 2.375 (1.713–3.291) \0.001
Lymph node stage
pN1 (reference) 1
pN1 1.378 (1.130–1.681) \0.001
pN2 2.634 (1.997–3.475) 0.002
Molecular subtype
Luminal A (reference) 1
Luminal B (HER2-) 1.086 (0.801–1.474) 0.594
Luminal B (HER2?) 1.3 (0.893–1.894) 0.171
HER2 type 1.207 (0.800–1.821) 0.369
Basal-like 1.871 (1.319–2.654) \0.001
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authors also used a non-commercially available antibody
which consists of a different clone, which could have led to a
different staining pattern. As all our positive cases showed a
strong staining intensity of 3?, we decided to estimate the
percentage of positive cells and to take all cases that showed
cytoplasmic staining C5 % of cancer cells as positive.
Our results show that expression of PTP1B in primary
breast cancers is associated with significantly better OS.
Therefore, in contrast to the experience with murine
models of breast cancer, PTP1B appears to play a tumor-
suppressive role in human breast cancer. This may be
through dephosphorylation of dysregulated protein tyrosine
kinases and concomitant inhibition of oncogenic signaling
pathways. One well-described substrate for PTP1B is
EGFR, a protein that is associated with worse OS in breast
cancer and has recently been implicated in the promotion
of breast cancer brain metastases [31, 32]. It could be that
PTP1B plays a role in the dephosphorylation of EGFR in
breast cancer, limiting invasion and migration of breast
cancer cells. In fact, several studies have shown that
PTP1B is able to strengthen and stabilize cell–cell adhesion
[33, 34]. Alternatively, the effect of PTP1B on breast
cancer could be mediated through the modulation of other
signaling pathways. For example, several reports suggest
Fig. 3 Kaplan–Meier survival
curve for OS depending on
PTP1B expression for the
intrinsic breast cancer subtypes.
PTP1B expression is an
independent prognostic factor
for OS in the luminal B HER2-
type. The luminal A subtype
also showed a strong trend
toward improved OS with
PTP1B expression
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that PTP1B promotes apoptosis through down-regulation
of pro-survival signaling [9, 10, 12].
The study by Wiener et al. [19] showed a significant
correlation between the expression of PTP1B and HER2, an
observation that was not replicated in our larger cohort of
1,402 evaluable cases. As such, our data does not support the
hypothesis put forward by several studies suggesting that
there is a biologic association, and possible functional
interaction, between these two proteins in breast cancer [19–
21, 23]. We did observe a small positive correlation between
the expression of PTP1B and ER in our series, and PTP1B
expression had a significant positive effect on OS in ER?, but
not ER- patients. This association has not been described in
the literature to date, and the mechanisms linking ER to
PTP1B have yet to be investigated.
The pharmaceutical industry has long focused on PTP1B as
a potential therapeutic target for diabetes and obesity. Several
companies have created potent and selective PTP1B inhibi-
tors, and the question has been raised whether these inhibitors
could also be used in breast cancer therapy [22, 35], particu-
larly for HER2? breast cancers [35]. Our results, however,
suggest that (1) expression of PTP1B in human breast cancer
might represent a favorable condition and (2) PTP1B may not
have any functional implication in human HER2? breast
cancers. Further studies investigating the functional mecha-
nisms of PTP1B in breast cancer are needed. Until we know
more about the role of this enzyme in human breast cancer,
caution should be exercised in using PTP1B inhibitors in a
clinical setting with breast cancer patients.
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